About Us
DxNow is combining novel, portable bio-imaging systems with microfluidic-based consumables for life science applications leveraging exclusively licensed technologies developed in the Demirci Bio-Acoustic MEMS in Medicine Labs (BAMM Labs) at Harvard Medical School/Brigham & Women’s Hospital and Stanford Medicine.
Our initial products address significant market needs in fertility clinics and forensics labs. We are in the process of establishing and expanding our commercialization efforts worldwide through key geographically-specific distribution partners.
Founded in 2013, DxNow is a privately-held Delaware C corporation whose corporate headquarters and primary research and development labs are located in Montgomery County, Maryland. This location offers close proximity to Washington, DC, the USFDA, USPTO, NIH, CMS and other agencies relevant to DxNow’s business interests, as well three major airports.
Our mission is to develop and commercialize novel tools that:
- Deliver improvements in assisted reproductive technology (ART) in humans and animals
- Facilitate faster identification of individuals for prosecution within the criminal justice system
- Enable advances in life science research and applied markets
- Provide faster, more cost-effective diagnostic solutions for chronically ill patients and their caregivers
Applications
Novel microfluidic and bio-imaging technologies address multiple markets
Assisted Reproductive Technologies (Human & Animal)
More than 70 million couples worldwide cannot conceive naturally and must use assisted reproductive technologies (ART) such as intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), or in vitro fertilization (IVF).1,2
In nearly 50% of cases, the problem is attributable to male factors.3 The frequency of male infertility is on the rise and is driving an increasing need for solutions to improve the outcome of ART procedures.
DxNow has designed and developed fertility products to deliver the best outcome for ICSI, IUI and IVF through the use of sperm separation and preparation to aid in selection of the healthiest motile sperm possible.
1 J. Boivin, L.B. Bunting, J.A. Collins, K.G. Nygren, Human Reprod. 2007, 22, 1506.
2 W.Ombelet, L.Cooke, S. Dyer, G.Serour, Human Reprod. Update 2008, 14, 605.
3 R.B. Meacham , G.F. Joyce , M. Wise, A. Kparker, C. Niederberger, J. Urol. 2007, 177 , 2058 – 2066.
Evidence Screening & Differential Extraction For DNA Analysis
More than 200,000 rapes and sexual assaults are reported each year in the United States. Worldwide, in excess of 840,000 cases involve sexual assault4. Every 107 seconds, another American is sexually assaulted. South Africa records the highest rates of rape in the world. According to children’s welfare groups, a woman is raped every 17 seconds in South Africa.
DxNow, in collaboration with The Demirci Bio-Acoustic MEMS in Medicine Labs (BAMM) at Stanford Medicine, has developed microfluidic-based platforms for the capture and sorting of a diverse type of cells and pathogens by utilizing highly specific recognition elements including antibodies and carbohydrates. These platform technologies have the potential of being deployed for the detection, capture and quantitation of multiple cell types from unprocessed samples. We have now applied these state-of-the-art technologies to selectively capture sperm from complex bodily fluids, a step which is crucial in forensic DNA analysis of sexual assault samples. Processing of sexual assault evidence generally requires separation of the victim’s cells (epithelial) from the perpetrator’s cells (sperm) and involves time consuming steps of selective cell lysis, centrifugation and separation into female and male DNA fractions (a process known as differential extraction). DxNow technology will provide a catalyst in helping to reduce DNA forensic backgrounds in cases involving sexual assault evidence. Methods for rapid and efficient processing of sexual assault evidence will accelerate forensic investigation and reduce casework backlogs.
DxNow leverages its expertise and proprietary technology in biology, microfluidics, imaging, surface chemistry and product design to supply tools for the research community. For example, both the FERTILE™ and FERTILE PLUS™ microfluidic devices may have applications in sperm toxicity for pharmacological R&D, sperm inhibition related to contraception, and genetic and epigenetic influences on sperm function. DxNow’s innovative proprietary lensless holographic shadow imaging in combination with modified surface chemistry has broad application in cell-based and particle-based capture assay detection.
Building on our expertise in cell sorting tools incorporating shadow imaging for detection and characterization of cells, we are developing medical diagnostic devices leveraging these technologies, along with microfluidic integrated biosensors, to capture and quantify cells from unprocessed whole blood or other body fluids. This healthcare platform technology addresses significant underserved clinical needs in the home and primary care settings for innovative, inexpensive, accurate and easy-to-use point-of-care diagnostics products.
Our technology platform is revolutionary. The inexpensive POC monitoring tools that we can deliver to the home or primary setting have not been available to date.
Our products will decrease healthcare costs and have significant clinical and socio-economic benefits.
This platform will deliver accurate, rapid and inexpensive test results, minimizing unnecessary and costly ER visits and hospitalizations. Specifically, our solutions consist of (i) a disposable single use microfluidic cartridge to capture WBCs and neutrophils and (ii) a portable, easy-to-use lens-free shadow imaging system to rapidly quantify captured cell counts. The easy-to-collect measurements and regular monitoring capabilities will provide much needed, timely treatment of patients before their conditions become acute.
Our lead product focuses on significant underserved medical needs in end-stage renal disease; specifically, addressing critical clinical barriers to more widespread use of peritoneal dialysis. Peritoneal dialysis is a preferred treatment modality that can be performed in the home setting, but is often not utilized due to the risk of peritonitis. By leveraging our technologies, we are delivering an inexpensive, disposable diagnostic that can be used in the home setting by patients to easily capture and analyze neutrophils from their dialysate to detect early indicators of peritoneal infection. Early detection of infections at their onset will enable clinicians to start early treatment, providing significant clinical benefits:
- Detecting infection at the onset and preventing the infection from developing to the chronic phase
- Monitoring and managing peritoneal dialysis therapy more easily within the home care environment
- Minimizing repeat infections, which can lead to peritoneal membrane degradation and forcing patients to switch to the more expensive and less convenient hemodialysis treatment.
Beyond monitoring for peritoneal infection, this proposed platform has broad potential application in monitoring patients receiving chemotherapy and transplants, where the need for a rapid and complete blood count is applicable, as well as detecting catheter infections rapidly in many other clinical procedures.
We combine novel, portable bio-imaging systems with microfluidic-based consumables for proprietary life sciences applications that:
- Deliver improvements in assisted reproductive technology (ART) in humans and animals
- Facilitate faster identification of individuals for prosecution within the criminal justice system
- Enable advances in life science research and applied markets
- Provide faster, more cost-effective diagnostic solutions for chronically ill patients and their caregivers
Our products are based on exclusively-licensed technologies developed in the Demirci BAMM Labs that:
- Address multiple parallel markets >$31B
- Enable detection and quantification across a broad spectrum and multiple bio-targets
- Eliminate sample preparation steps
- Enable use of unprocessed whole blood, saliva, semen, serum, urine
- Provide for in vitro cultures on chip / dish / plate
Our Products
Technologies enable detection and quantification of multiple bio-targets
ZyMōt™ Fertility – The Future of Fertility Has Arrived
According to data published by the World Health Organization (WHO), as many as one in five healthy males aged 18 to 25 years old have abnormal sperm counts and only 5 to 15% of sperm are considered normal.
To address the problem, we are commercializing two products in the USA market: ZyMōt™ ICSI and ZyMōt™ Multi Sperm Separation Devices.
Utilizing currently available methods, the embryologist is challenged to select the “right” sperm for use in ART procedures. Furthermore, current procedures requiring centrifugation cause irreversible damage to the sperm due to DNA fragmentation and the generation of reactive oxygen species (ROS). DxNow has developed novel devices for use in assisted reproductive technology (ART) procedures conducted by fertility clinics and OB/GYN practices. The ZyMōt devices are intended for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and in vitro fertilization (IVF) procedures. These devices will be the first of their kind in the U.S. market.
The ZyMōt devices simulate the cervical and uterine pathway that sperm must navigate to naturally fertilize an egg, recreating a process that has been preserved in nature for millions of years. With the goal of mimicking nature, ZyMōt devices facilitate the separation and preparation of highly-motile sperm with normal morphology for use in ART procedures. Presenting a simple and straight-forward methodology, the ZyMōt devices provide considerable time savings when compared to conventional methods.
- Our fertility devices eliminate the need for time-consuming sample preparation and sperm damaging centrifugation.
- The result is a simple and fast method, enabling the embryologist to consistently select sperm with higher motility, better morphology, less damaging ROS generation and lower DNA fragmentation.
Advantages of Our Fertility Devices
- Separation of the “right” sperm and…
- require no sample preparation
- standardize and simplify processing
- require no sperm damaging centrifugation
- sperm separated in volumes required by ICSI, IUI and IVF
- channel dimensions and incubation timing optimized for maximum separation efficiency
- select sperm with high motility, normal morphology, low ROS, low DNA fragmentation
In parallel to our activities in the human market, we are working with key opinion leaders (KOLs) in the veterinary market to validate the utility and function of these products for ART applications in animals.
ZyMōt Device Descriptions:
ZyMōt ICSI and ZyMōt Multi Sperm Separation Devices are used to prepare motile sperm for assisted reproductive technology (ART) procedures. Both devices separate sperm based on motility. The ZyMōt ICSI and the ZyMōt Multi are sterile and single use only. The mechanism of action for both is separation of sperm based on motility within a microenvironment created by the micro-channels of the ZyMōt ICSI or the micro-pores in the filter of the ZyMōt Multi. The primary difference between the devices is the processing volume. The ZyMōt ICSI has a processing volume of 2µl per micro-channel. The ZyMōt Multi is manufactured in two (2) processing volumes, 850µl and 3ml.
The ZyMōt ICSI has 5 micro-channels; each accommodating 2µl of semen. More than one micro-channel is available to accommodate multiple separations. Each channel has an inlet port for applying the semen sample and an outlet port for collecting the motile sperm. The ports are connected by a fluid-filled micro-channel in which the separating occurs. Untreated semen is added through the inlet port. After a period of time, the separated sperm are collected from the outlet port.
The ZyMōt Multi (provided with 850µl and 3ml collection chambers) has an inlet port that communicates with the lower sample chamber. The sample chamber is separated from the upper collection chamber by a microporous filter. Untreated semen is added through the inlet port. After a period of time, the separated sperm are collected from the upper chamber through the outlet port.
Indications for Use:
The ZyMōt ICSI Sperm Separation Device is intended for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection (ICSI) procedures.
The ZyMōt Multi (850µl) Sperm Separation Device is intended for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF) and intrauterine insemination (IUI) procedures.
Interested in obtaining ZyMōt™ Sperm Separation Devices? Contact our team for more information.
FERTILE™ and FERTILE PLUS™
According to data published by the World Health Organization (WHO), as many as one in five healthy males aged 18 to 25 years old have abnormal sperm counts and only 5 to 15% of sperm are considered normal.
To address the problem, we have developed and are commercializing two products – FERTILE™ for ICSI and FERTILE PLUS™ for ICSI, IUI and IVF (aka (ZyMōt™ ICSI and ZyMōt™ Multi in the USA).
Utilizing currently available methods, the embryologist is challenged to select the “right” sperm for use in ART procedures. Furthermore, current procedures requiring centrifugation cause irreversible damage to the sperm due to DNA fragmentation and the generation of reactive oxygen species (ROS).
Our fertility devices eliminate the need for time-consuming sample preparation and sperm damaging centrifugation.
The result is a simple and fast method, enabling the embryologist to consistently select sperm with higher motility, better morphology, less damaging ROS generation and lower DNA fragmentation.
In parallel to our activities in the human market, we are working with key opinion leaders (KOLs) in the veterinary market to validate the utility and function of these products for ART applications in animals.
FERTILE and FERTILE PLUS are CE registered and currently in use in clinics within Europe and Latin America.
Advantages of Our Fertility Devices
- Chips sort to yield population of “right” sperm and…
- require no sample preparation
- standardize and simplify processing
- require no sperm damaging centrifugation
- sperm sorted in volumes required by ICSI, IUI and IVF
- channel dimensions and incubation timing optimized for maximum sorting efficiency
- select sperm with high motility, normal morphology, low ROS, low DNA fragmentation
Distributors
Exclusive Sublicensee
KOEK Biotechnology
Contact: Selcuk Kilinc, M.D.
Address: Dokuz Eylul University, Inciralti Campus / DEPARK Health Olive Building / Mithatpasa Street No: 56/20-215 / Balcova / IZMIR TURKEY
Phone: +90 232 236 7814
E-mail: info@koekbiotech.com
Website: www.koekbiotech.com
Territory: Turkey, Egypt, Iraq, Saudi Arabia, Yemen, United Arab Emirates, Israel, Jordan, Palestine, Lebanon, Kuwait, Oman, Qatar, Bahrain, Cyprus, Russia, Armenia, Azerbaijan, Georgia
Europe
SeBeBio
Contact: Seza Onur
Address: 51 Route de la Chapelle / 1212 Grand Lancy GE / Switzerland
Phone: (+)41 76 272 3883
E-mail: onur.s@sebebio.ch
Website: www.sebebio.ch
Territory: Switzerland, Austria, France, Germany
Mitrone
Contact: Barry Jordan
Address: 9 Ardagh Avenue / Blackrock Co / Dublin. Ireland
Phone: Office: (+)353 1 283 61 07, Cell: (+)353(0)86 837 42 70
E-mail: barry@mitrone.ie
Territory: UK, Ireland
SUPPLEKEY HEALTH
Contacts: Daphne Charoupa /Maria Sotirhos
Address: Kyrpou 11 / Neo Rysio, Thessaloniki 57001 / Greece
Phone: DC: O: (+)30 23920 72089, C: (+)30 694 598 0504 / MS: C: (+) 30 694 082 6806
E-mail: info@supplekey.gr
Territory: Greece, Greek Cyprus
East Port Praha s.r.o.
Contact: Marcel Kunay
Address: Možného 10 / 161 00 Praha 6 / Czech Republic
Phone: Office: (+)420 235 318 177
E-mail: marcel.kunay@eastport.cz
Territory: Czech Republic, Slovakia
ART Solutions
Contact: Tomasz Wejman
Address: Al. KEN 36/112B / 02-797 Warszawa /Poland
Phone: (+)48 530 074 074
E-mail: t.wejman@artsolutions.com.pl
Territory: Poland
CIMAB / Centre d’Infertilitat Masculina i Analisis de Barcelona S.L.
Contact: Dr. Agustín Garcia
Address: Calle Vallcorba 1-3 / 08192 SANT QUIRZE DEL VALLÉS / Spain
Phone: (+)+34 93 858 7614
E-mail: info@cimab.es
Territory: Spain & Portugal
K4technology ApS / Subsidiary of IVF Tech
Contact: Søren Johannsen
Address: Toppevadvej 34-38 / Stenløse DK-3660 / Denmark
Phone: (+)45 39 40 25 63
E-mail: soren@k4technology.dk
Territory: Denmark, Sweden, Norway & Finland
Latin America
Nanog Biotec
Contact: Diego Carrillo
Address: Justo Sierra No. 3383 / Col. Vallarta San Jorge / Guadalajara, Jalisco. México / 44690
Phone: (+)52 33 1955 7151
E-mail: diego@nanogbiotec.com
Territory: Mexico
CRYO BIOART, S.A.C
Contact: María Milagritos Escobar
Address: Calle Gamma 266 ofic. 302 / Parque Industrial del Callao / Zip Code. Callao 1 / Callao, Perú
Phone: (+)51 994 208 131 cryo.bioart@gmail.com
E-mail: cryo.bioart@gmail.com
Territory: Peru
South Asia
Trivector Biomed LLP
Contact: Dilip Patil
Address: 111-115, Marathon Max, Mulund West, Mumbai - 400080, India
Phone: (+)91-22-25683997
E-mail: trivector2001@yahoo.com
Territory: India, Sri Lanka, Bangladesh, Nepal, Bhutan, Maldives
- Chips sort to yield population of “right” sperm and…
CSI-Q™ (Chip-Based Sperm Identification and Quantitation) Cartridges
“Forensic evidence is collected from crime scenes, victims and suspects in criminal cases and then submitted to a laboratory. Processing this evidence is time-consuming because it must first be screened to determine whether any biological material is present and, if so, what kind of biological material it is. Only then can DNA testing begin.”The DxNow CSI-Q™ cartridge is designed to aid the forensic DNA analyst to rapidly identify the most probative sample(s) in forensic DNA casework to submit for further DNA Analysis. CSI-Q is based on the same scientific principles of the innovative NGDE™ technology. Sexual assault evidence samples will be extracted by standard laboratory procedure and an aliquot will be loaded on the chip and washed. If sperm are present in the extract, they will be captured by the oligonucleotide present in the channel and all other cell types will be washed from the chip.
―National Institute of Justice; http://www.nij.gov/topics/forensics/lab-operations/evidence-backlogs/pages/forensic-evidence-backlog.aspx
Upon inspection of the chip under a microscope, those samples in which sperm are detected will then be submitted to the testing laboratory for subsequent analysis. The CSI-Q disposable cartridges represent a confirmatory test for the presence of sperm, helping the laboratory to process the most relevant samples, increasing the efficiency and effectiveness of the forensic DNA process.NGDE™ (Next-Generation Differential Extraction) System
Processing of sexual assault evidence generally requires separation of the victim’s cells (epithelial) from the perpetrator’s cells (sperm) and involves time-consuming steps of selective cell lysis, centrifugation and separation into female and male DNA fractions. To address the challenge of automating and scaling-up this process, DxNow has developed a novel microfluidic system for isolation and quantitation of sperms from forensic evidence.
One exciting aspect of this work is the novel approach we use for sperm capture. Recent investigations have demonstrated that a unique oligosaccharide located on the extracellular matrix of the oocyte represents a ligand for human sperm-egg binding. At DxNow, we will commercialize a disposable microfluidic-based cartridge that can capture sperm cells using this oligosaccharide sequence. Microfluidic-based technologies hold a crucial potential by integrating multiple steps on a single device, improving the scaling capacity, integrating many detection platforms, minimizing reagent consumption and reducing the need for skilled personnel.
With the NGDE system, the forensic differential extraction process will be reduced to under 1 hour and will only require approximately 15 minutes of technician time. Adoption of CSI-Q will enable significant reductions in casework backlogs and more timely processing of new cases.
Quality Statement
DxNow is committed to providing products that fully meet the requirements and expectations of our customers, in compliance with applicable national and international regulations and requirements, as described in our quality manual and quality management procedures.
Our policy objective is to continuously improve upon quality via regular evaluation of established quality objectives with respect to the adequacy of our resources, training, knowledge and skills and customer satisfaction.
Investors
DISCLAIMER
Not an Offer to Purchase or Sell Securities. This overview is for informational purposes and is not an offer to sell or a solicitation of an offer to buy any securities in DxNow, Inc. the “Company” and/or any affiliates. Any offering or solicitation will be made only to qualified prospective investors pursuant to a confidential offering memorandum, and the subscription documents, all of which should be read in their entirety. This business plan contains proprietary information of DxNow, Inc. Neither this business plan nor any of the information contained herein may be reproduced or disclosed to any person without the written consent of DxNow, Inc.
DxNow, Inc. – Introduction and overview
Media
Videos & Multimedia
DxNow, Inc. – Introduction and Overview
FERTILE™ and FERTILE PLUS™ Products – Introduction and OverviewReference Publications
BOOKS
Demirci, U. (Author, Editor), Khademhosseini, A. (Editor), Langer, R. (Editor), and Blander, J. (Editor)“Microfluidic Technologies for Human Health”. Publisher: World Scientific Publishing Company, ISBN-10: 9814405515, ISBN-13: 978-9814405515 (Cover)
JOURNAL ARTICLES
Tasoglu S., Diller E., Guven S., Sitti M., and Demirci U., Untethered micro-robotic coding of three-dimensional material composition. Nat. Commun. 5:3124 doi: 10.1038/ncomms4124. (PDF).
Wang S., Tasoglu S., Chen P. Z., Chen M., Akbas R., Wach S., Ozdemir C. I., Gurkan U. A., Giguel F. F., Kuritzkes D. R., and Demirci U., Micro-a-fluidics ELISA for Rapid CD4 Cell Count at the Point-of-Care. Sci. Rep. 4, 3796; DOI:10.1038/srep03796. (PDF).
Akkaynak, D., Treibitz, T., Xiao, B., Gurkan, U. A., Allen, J., Demirci, U., and Hanlon, R., Use of commercial off-the-shelf (COTS) digital cameras for scientific data acquisition and scene-specific colour calibration. Journal of the Optical Society of America A. 2014; 31(2): 312-321. (PDF).
Shafiee, H., Lidstone, E.A., Jahangir, M., Inci, F., Hanhauser, E., Henrich, T.J., Kuritzkes, D.R., Cunningham, B.T., and Demirci, U., Nanostructured Optical Photonic Crystal Biosensor for HIV Viral Load Measurement. Sci. Rep. 4, 4116, DOI: 10.1038/srep04116. (PDF).
Kilinc S., Gurkan U. A., Koyuncu G., Dogan M., Tugmen C., Kebapci E., Karaca C., Tan S., Pala E. E., Bayol U., Baran M., Kurtulmus Y., Pirim I., Guven S., and Demirci U., Chimerism after BMSC transfusion in intestinal transplant patients with short bowel syndrome. American Journal of Transplantation. (in press).
Asghar W., Velasco V., Kingslye J.L., Shoukat M.S., Shafiee H., Anchan R.M., Mutter G.L., Tuzel E., and Demirci U., Selection of functional human sperm with higher DNA integrity and fewer reactive oxygen species. Advanced Healthcare Materials. (in press).
Shafiee, H., Jahangir, M., Inci, F., Wang, S., Willenbrecht, R.B., Giguel, F.F., Tsibris, A.M., Kuritzkes, D.R., and Demirci, U., Acute On-Chip HIV Detection Through Label-Free Electrical Sensing of Viral Nano-Lysate. Small, 2013.; doi:10.1002/smll.201202195 (PDF).
Tasoglu, S., Kavaz, D., Gurkan, U.A., Guven, S., Chen, P., Zheng, R., and Demirci, U., Paramagnetic levitational assembly of hydrogels. Adv Mater, 2013. 25(8): p. 1137-43, 1081.; doi: 10.1002/adma.201200285 (PDF).
Tasoglu, S., Safaee, H., Zhang, X., Kingsley, J.L., Catalano, P.N., Gurkan, U.A., Nureddin, A., Kayaalp, E., Anchan, R.M., Maas, R.L., Tüzel, E.*, and Demirci, U.*, Exhaustion of Racing Sperm in Nature-Mimicking Microfluidic Channels During Sorting. Small, 2013: p. n/a-n/a., DOI: 10.1002/smll.201300020 (2013). (PDF)
Tasoglu, S. and Demirci, U., Bioprinting for stem cell research. Trends Biotechnol, 2013. 31(1): p. 10-9. doi:10.1016/j.tibtech.2012.10.005 (PDF)
Tasoglu, S., Gurkan, U.A., Wang, S., and Demirci, U., Manipulating biological agents and cells in micro-scale volumes for applications in medicine. Chem Soc Rev, 2013., DOI:10.1039/C3CS60042D. (PDF)
Durmus, N.G., Tasoglu, S., and Demirci, U., Bioprinting: Functional droplet networks. Nat Mater, 2013.12(6): p. 478-479. DOI:10.1038/nmat3665 (PDF)
Wang, L.*, Asghar, W.*, Demirci, U.#, and Wan, Y.#, Nanostructured Substrate for Isolation of Circulating Tumor Cells. Nano Today, Volume 8, Issue 4, August 2013, Pages 374–387(# Corresponding authors) (PDF)
Rizvi, I., Gurkan, U.A., Tasoglu, S., Alagic, N., Celli, J.P., Mensah, L.B., Mai, Z., Demirci, U.#, and Hasan, T.#, Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules. Proc Natl Acad Sci U S A, 2013. (#Corresponding authors) (PDF).
Inci, F.*, Tokel, O.*, Wang, S., Gurkan, U.A., Tasoglu, S., Kuritzkes, D.R., and Demirci, U.,Nanoplasmonic Quantitative Detection of Intact Viruses from Unprocessed Whole Blood. ACS Nano, 2013., DOI: 10.1021/nn3036232. (PDF)
Gurkan, U.A., Fan, Y., Xu, F., Erkmen, B., Urkac, E.S., Parlakgul, G., Bernstein, J., Xing, W., Boyden, E.S., and Demirci, U., Simple precision creation of digitally specified, spatially heterogeneous, engineered tissue architectures. Adv Mater, 2013. 25(8): p. 1192-8.; doi:10.1002/adma.201203261 (PDF)
Guven, S. and Demirci, U., Integrating nanoscale technologies with cryogenics: a step towards improved biopreservation. Nanomedicine (Lond), 2012. 7(12): p. 1787-9. (PDF).
Wang, S., Sarenac, D., Chen, M.H., Huang, S.H., Giguel, F.F., Kuritzkes, D.R., and Demirci, U., Simple filter microchip for rapid separation of plasma and viruses from whole blood. Int J Nanomedicine, 2012.7: p. 5019-28. (PDF).
Ceyhan, E., Xu, F., Gurkan, U.A., Emre, A.E., Turali, E.S., El Assal, R., Acikgenc, A., Wu, C.-a.M., and Demirci, U., Prediction and control of number of cells in microdroplets by stochastic modeling. Lab on a Chip, 2012. 12(22): p. 4884-4893; doi:10.1039/c2lc40523g (PDF).
Gurkan, U.A., Tasoglu, S., Akkaynak, D., Avci, O., Unluisler, S., Canikyan, S., MacCallum, N., and Demirci, U., Smart Interface Materials Integrated with Microfluidics for On-Demand Local Capture and Release of Cells. Advanced Healthcare Materials, 2012. 1(5): p. 661-668.; doi: 10.1002/adhm.201200009 (PDF).
Gurkan, U.A.*, Tasoglu, S.*, Kavaz, D., Demirel, M.C., and Demirci, U., Emerging Technologies for Assembly of Microscale Hydrogels. Advanced Healthcare Materials, 2012. 1(2): p. 149-158.; doi: 10.1002/adhm.201200011 (PDF).
Xu, F., Inci, F., Mullick, O., Gurkan, U.A., Sung, Y., Kavaz, D., Li, B., Denkbas, E.B., and Demirci, U.,Release of Magnetic Nanoparticles from Cell-Encapsulating Biodegradable Nanobiomaterials. ACS Nano, 2012. 6(8): p. 6640-6649.; doi: 10.1021/nn300902w (PDF).
Wang, S., Inci, F., Chaunzwa, T.L., Ramanujam, A., Vasudevan, A., Subramanian, S., Chi Fai Ip, A., Sridharan, B., Gurkan, U.A., and Demirci, U., Portable microfluidic chip for detection of Escherichia coli in produce and blood. Int J Nanomedicine, 2012. 7: p. 2591-600.; doi:10.2147/IJN.S29629 (PDF).
Guldiken, R., Jo, M.C., Gallant, N.D., Demirci, U., and Zhe, J., Sheathless Size-Based Acoustic Particle Separation. Sensors, 2012. 12(1): p. 905-922; doi:10.3390/s120100905 (PDF).
Wang, S.*, Esfahani, M.*, Gurkan, U.A., Inci, F., Kuritzkes, D.R., and Demirci, U., Efficient on-chip isolation of HIV subtypes. Lab Chip, 2012. 12(8): p. 1508-15; doi:10.1039/C2LC20706K (PDF).
Zhang, X., Khimji, I., Shao, L., Safaee, H., Desai, K., Keles, H.O., Gurkan, U.A., Kayaalp, E., Nureddin, A., Anchan, R.M., Maas, R.L., and Demirci, U., Nanoliter droplet vitrification for oocyte cryopreservation. Nanomedicine (Lond), 2012. 7(4): p. 553-64; doi:10.2217/NNM.11.145 (PDF).
Wang, S., Zhao, X., Khimji, I., Akbas, R., Qiu, W., Edwards, D., Cramer, D.W., Ye, B., and Demirci, U.,Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care. Lab Chip, 2011. 11(20): p. 3411-8.; doi: 10.1039/C1LC20479C (PDF)
Gurkan, U.A., Anand, T., Tas, H., Elkan, D., Akay, A., Keles, H.O., and Demirci, U., Controlled viable release of selectively captured label-free cells in microchannels. Lab Chip, 2011. 11(23): p. 3979-89.(PDF)
Xu, F., Wu, C.A., Rengarajan, V., Finley, T.D., Keles, H.O., Sung, Y., Li, B., Gurkan, U.A., and Demirci, U., Three-dimensional magnetic assembly of microscale hydrogels. Adv Mater, 2011. 23(37): p. 4254-60.; doi:10.1002/adma.201101962 (PDF)
Zhang, X., Catalano, P.N., Gurkan, U.A., Khimji, I., and Demirci, U., Emerging technologies in medical applications of minimum volume vitrification. Nanomedicine (Lond), 2011. 6(6): p. 1115-29. (PDF)
Xu, F., Finley, T.D., Turkaydin, M., Sung, Y., Gurkan, U.A., Yavuz, A.S., Guldiken, R.O., and Demirci, U., The assembly of cell-encapsulating microscale hydrogels using acoustic waves. Biomaterials, 2011.32(31): p. 7847-55. (PDF)
Moon, S., Ceyhan, E., Gurkan, U.A., and Demirci, U., Statistical modeling of single target cell encapsulation. PLoS One, 2011. 6(7): p. e21580. (PDF)
Moon, S., Gurkan, U.A., Blander, J., Fawzi, W.W., Aboud, S., Mugusi, F., Kuritzkes, D.R., and Demirci, U., Enumeration of CD4+ T-Cells Using a Portable Microchip Count Platform in Tanzanian HIV-Infected Patients. PLoS ONE, 2011. 6(7): p. e21409. (PDF)
Zhang, X., Khimji, I., Gurkan, U.A., Safaee, H., Catalano, P.N., Keles, H.O., Kayaalp, E., and Demirci, U., Lensless imaging for simultaneous microfluidic sperm monitoring and sorting. Lab Chip, 2011.11(15): p. 2535-40. (PDF)
Xu, F., Sridharan, B., Durmus, N.G., Wang, S., Yavuz, A.S., Gurkan, U.A., and Demirci, U., Living Bacterial Sacrificial Porogens to Engineer Decellularized Porous Scaffolds. PLoS ONE, 2011. 6(4): p. e19344.(PDF)
Moon, S.*, Kim, Y.-G.*, Dong, L., Lombardi, M., Haeggstrom, E., Jensen, R.V., Hsiao, L.-L., and Demirci, U., Drop-on-Demand Single Cell Isolation and Total RNA Analysis. PLoS ONE, 2011. 6(3): p. e17455. (PDF)
Samot, J., Moon, S., Shao, L., Zhang, X., Xu, F., Song, Y., Keles, H.O., Matloff, L., Markel, J., and Demirci, U., Blood Banking in Living Droplets. PLoS ONE, 2011. 6(3): p. e17530. (PDF)
Gurkan, U.A., Moon, S., Geckil, H., Xu, F., Wang, S., Lu, T.J., and Demirci, U., Miniaturized lensless imaging systems for cell and microorganism visualization in point-of-care testing. Biotechnol J, 2011.6(2): p. 138-49. (PDF)
Xu, F., Celli, J., Rizvi, I., Moon, S., Hasan, T., and Demirci, U., A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform. Biotechnol J, 2011. 6(2): p. 204-12. (PDF)
Demirci, U. and Geckil, H., Editorial: Micro and nanofluidics – applications in biotechnology.Biotechnology Journal, 2011. 6(2): p. 131-131. (PDF)
Wang, S., Xu, F., and Demirci, U., Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv, 2010. 28(6): p. 770-81. (PDF)
Song, Y.S., Adler, D., Xu, F., Kayaalp, E., Nureddin, A., Anchan, R.M., Maas, R.L., and Demirci, U.,Vitrification and levitation of a liquid droplet on liquid nitrogen. Proceedings of the National Academy of Sciences, 2010. (PDF)
Geckil, H.*, Xu, F.*, Zhang, X., Moon, S., and Demirci, U., Engineering hydrogels as extracellular matrix mimics. Nanomedicine (Lond), 2010. 5(3): p. 469-84. (PDF)
Lee, W.G., Kim, Y.G., Chung, B.G., Demirci, U., and Khademhosseini, A., Nano/Microfluidics for diagnosis of infectious diseases in developing countries. Adv Drug Deliv Rev, 2010. 62(4-5): p. 449-57.(PDF)
Moon, S., Hasan, S.K., Song, Y.S., Xu, F., Keles, H.O., Manzur, F., Mikkilineni, S., Hong, J.W., Nagatomi, J., Haeggstrom, E., Khademhosseini, A., and Demirci, U., Layer by layer three-dimensional tissue epitaxy by cell-laden hydrogel droplets. Tissue Eng Part C Methods, 2010. 16(1): p. 157-66.(PDF)
Lee, W.G., Demirci, U., and Khademhosseini, A., Microscale electroporation: challenges and perspectives for clinical applications. Integr Biol (Camb), 2009. 1(3): p. 242-51. (PDF)
Alyassin, M.A., Moon, S., Keles, H.O., Manzur, F., Lin, R.L., Haeggstrom, E., Kuritzkes, D.R., and Demirci, U., Rapid automated cell quantification on HIV microfluidic devices. Lab Chip, 2009. 9(23): p. 3364-9. (PDF)
Song, Y.S., Lin, R.L., Montesano, G., Durmus, N.G., Lee, G., Yoo, S.S., Kayaalp, E., Haeggstrom, E., Khademhosseini, A., and Demirci, U., Engineered 3D tissue models for cell-laden microfluidic channels.Anal Bioanal Chem, 2009. 395(1): p. 185-93. (PDF)
Kim, Y.G., Moon, S., Kuritzkes, D.R., and Demirci, U., Quantum dot-based HIV capture and imaging in a microfluidic channel. Biosens Bioelectron, 2009. 25(1): p. 253-8. (PDF)
Moon, S., Keles, H.O., Ozcan, A., Khademhosseini, A., Haeggstrom, E., Kuritzkes, D., and Demirci, U.,Integrating microfluidics and lensless imaging for point-of-care testing. Biosens Bioelectron, 2009.24(11): p. 3208-14. (PDF)
Manbachi, A., Shrivastava, S., Cioffi, M., Chung, B.G., Moretti, M., Demirci, U., Yliperttula, M., and Khademhosseini, A., Microcirculation within grooved substrates regulates cell positioning and cell docking inside microfluidic channels. Lab on a Chip, 2008. 8(5): p. 747-754. (PDF)
Ozcan, A. and Demirci, U., Ultra wide-field lens-free monitoring of cells on-chip. Lab Chip, 2008. 8(1): p. 98-106.(PDF)
Demirci, U. and Montesano, G., Cell encapsulating droplet vitrification. Lab Chip, 2007. 7(11): p. 1428-33. (PDF)
Cheng, X., Liu, Y.S., Irimia, D., Demirci, U., Yang, L., Zamir, L., Rodriguez, W.R., Toner, M., and Bashir, R., Cell detection and counting through cell lysate impedance spectroscopy in microfluidic devices. Lab Chip, 2007. 7(6): p. 746-55. (PDF)
Ling, Y., Rubin, J., Deng, Y., Huang, C., Demirci, U., Karp, J.M., and Khademhosseini, A., A cell-laden microfluidic hydrogel. Lab Chip, 2007. 7(6): p. 756-62. (PDF)
Cheng, X., Irimia, D., Dixon, M., Sekine, K., Demirci, U., Zamir, L., Tompkins, R.G., Rodriguez, W., and Toner, M., A microfluidic device for practical label-free CD4(+) T cell counting of HIV-infected subjects. Lab Chip, 2007. 7(2): p. 170-8. (PDF)
Demirci, U., Acoustic picoliter droplets for emerging applications in semiconductor industry and biotechnology. Journal of microelectromechanical systems, 2006. 15(4): p. 957-966. (PDF)
Demirci, U. and Toner, M., Direct etch method for microfludic channel and nanoheight post-fabrication by picoliter droplets. Applied Physics Letters, 2006. 88(5): p. 053117-3.(Also at Virtual Journal of Nanoscale Science and Technology and Virtual Journal of Biological Physics Research) (PDF)
Oralkan, O., Ergun, A.S., Johnson, J.A., Karaman, M., Demirci, U., Kaviani, K., Lee, T.H., and Khuri-Yakub, B.T., Capacitive micromachined ultrasonic transducers: next-generation arrays for acoustic imaging? IEEE Trans Ultrason Ferroelectr Freq Control, 2002. 49(11): p. 1596-610.
Johnson, J., Oralkan, O., Demirci, U., Ergun, S., Karaman, M., and Khuri-Yakub, P., Medical imaging using capacitive micromachined ultrasonic transducer arrays. IEEE Trans Ultrason Ferroelectr Freq Control Ultrasonics, 2002. 40(1-8): p. 471-6.
Our Publications
Microfluidic Sperm Sorting Device For Selection of Functional Human Sperm IUI Application
Sorting of equine sperm using a microfluidic device as a method of sperm selection for IVF and ICSI
Selective Isolation Of Sperm From Biological Samples Using A Unique Oligosaccharide Capture Reagent In A Microfluidic Platform
Assisted Reproductive Microchip Technologies to Improve InfertilityNews & Events
http://pulse.embs.org/january-2015/assisted-reproductive-technologies-improve-infertility/
http://www.bostonmagazine.com/health/blog/2013/05/22/sperm-sorting-infertility
Finding the fastest sperm to help increase IVF success
Racing sperm to boost results of in vitro fertilization
Press Releases